Nurix therapeutics to participate in upcoming investor conferences

San francisco, march 06, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that hans van houte, nurix's chief financial officer, and jason kantor, ph.d., nurix's chief business officer will participate in the following conferences in march: leerink partners global biopharma conference 2024 one-on-one meetings only: tuesday, march 12, 2024 barclays global healthcare conference fireside chat: wednesday, march 13, 2024, from 4:05 – 4:30 p.m.
NRIX Ratings Summary
NRIX Quant Ranking